open access

Vol 14, No 3 (2019)
Heart failure
Published online: 2019-07-04
Get Citation

Peripartum cardiomyopathy — still unknown. Current state of knowledge

Kiet Anh Nguyen, Kamila Gniady, Małgorzata Lelonek
DOI: 10.5603/FC.2019.0064
·
Folia Cardiologica 2019;14(3):305-314.

open access

Vol 14, No 3 (2019)
Heart failure
Published online: 2019-07-04

Abstract

Peripartum cardiomyopathy (PPCM) is defined as idiopathic cardiomyopathy which occurs at the end of pregnancy or in the first few months after delivery, with symptoms of heart failure (HF) secondary to left ventricular dysfunction, and at the same time no other cause for this condition. The pathomechanism of the disease has not yet been fully understood, but it is probably based on the interaction of complex factors. The clinical course of PPCM varies from life-threatening acute heart failure to mild symptoms mimicking the symptoms typical of the perinatal period. In Europe, PPCM is a rare disease but there are areas of the world where it occurs in one in every 300 cases. The treatment of PPCM is similar to that of HF with reduced ejection fraction. However, it is important to exclude drugs with teratogenic effects during pregnancy. The inclusion of bromocriptine in PPCM therapy seems to be justified, and in some cases improves the prognosis.

Abstract

Peripartum cardiomyopathy (PPCM) is defined as idiopathic cardiomyopathy which occurs at the end of pregnancy or in the first few months after delivery, with symptoms of heart failure (HF) secondary to left ventricular dysfunction, and at the same time no other cause for this condition. The pathomechanism of the disease has not yet been fully understood, but it is probably based on the interaction of complex factors. The clinical course of PPCM varies from life-threatening acute heart failure to mild symptoms mimicking the symptoms typical of the perinatal period. In Europe, PPCM is a rare disease but there are areas of the world where it occurs in one in every 300 cases. The treatment of PPCM is similar to that of HF with reduced ejection fraction. However, it is important to exclude drugs with teratogenic effects during pregnancy. The inclusion of bromocriptine in PPCM therapy seems to be justified, and in some cases improves the prognosis.

Get Citation

Keywords

peripartum cardiomyopathy; PPCM; heart failure; pregnancy; bromocriptine

About this article
Title

Peripartum cardiomyopathy — still unknown. Current state of knowledge

Journal

Folia Cardiologica

Issue

Vol 14, No 3 (2019)

Pages

305-314

Published online

2019-07-04

DOI

10.5603/FC.2019.0064

Bibliographic record

Folia Cardiologica 2019;14(3):305-314.

Keywords

peripartum cardiomyopathy
PPCM
heart failure
pregnancy
bromocriptine

Authors

Kiet Anh Nguyen
Kamila Gniady
Małgorzata Lelonek

References (31)
  1. Arany Z, Elkayam U. Peripartum Cardiomyopathy. Circulation. 2016; 133(14): 1397–1409.
  2. Murali S, Baldisseri MR. Peripartum cardiomyopathy. Crit Care Med. 2005; 33(10 Suppl): S340–S346.
  3. Sliwa K, Hilfiker-Kleiner D, Petrie MC, et al. Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail. 2010; 12(8): 767–778.
  4. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000; 283(9): 1183–1188.
  5. Hilfiker-Kleiner D, Sliwa K. Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol. 2014; 11(6): 364–370.
  6. Koenig T, Bauersachs J, Hilfiker-Kleiner D, et al. Peripartum cardiomyopathy. Herz. 2018; 43(5): 431–437.
  7. Hilfiker-Kleiner D, Haghikia A, Berliner D, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017; 38(35): 2671–2679.
  8. Patten IS, Rana S, Shahul S, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012; 485(7398): 333–338.
  9. Kim MJ, Shin MS. Practical management of peripartum cardiomyopathy. Korean J Intern Med. 2017; 32(3): 393–403.
  10. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007; 128(3): 589–600.
  11. Bello NA, Arany Z. Molecular mechanisms of peripartum cardiomyopathy: A vascular/hormonal hypothesis. Trends Cardiovasc Med. 2015; 25(6): 499–504.
  12. Patel H, Berg M, Barasa A, et al. Symptoms in women with Peripartum Cardiomyopathy: A mixed method study. Midwifery. 2016; 32: 14–20.
  13. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. ESC Scientific Document Group . 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39(34): 3165–3241.
  14. Ware JS, Li J, Mazaika E, et al. IMAC-2 and IPAC Investigators. Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. N Engl J Med. 2016; 374(3): 233–241.
  15. Schelbert EB, Elkayam U, Cooper LT, et al. Investigations of Pregnancy Associated Cardiomyopathy (IPAC) Investigators. Myocardial Damage Detected by Late Gadolinium Enhancement Cardiac Magnetic Resonance Is Uncommon in Peripartum Cardiomyopathy. J Am Heart Assoc. 2017; 6(4).
  16. van Spaendonck-Zwarts KY, van Tintelen JP, van Veldhuisen DJ, et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation. 2010; 121(20): 2169–2175.
  17. Bültmann BD, Klingel K, Näbauer M, et al. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. Am J Obstet Gynecol. 2005; 193(2): 363–365.
  18. Azibani F, Sliwa K. Peripartum Cardiomyopathy: an Update. Curr Heart Fail Rep. 2018; 15(5): 297–306.
  19. Halkein J, Tabruyn SP, Ricke-Hoch M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013; 123(5): 2143–2154.
  20. Walenta K, Schwarz V, Schirmer SH, et al. Circulating microparticles as indicators of peripartum cardiomyopathy. Eur Heart J. 2012; 33(12): 1469–1479.
  21. Sliwa K, Petrie MC, Hilfiker-Kleiner D, et al. Long-term prognosis, subsequent pregnancy, contraception and overall management of peripartum cardiomyopathy: practical guidance paper from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. Eur J Heart Fail. 2018; 20(6): 951–962.
  22. Leśniak-Sobelga A, Gąsior Z, Kostkiewicz M, et al. Współczesna kardiologiczna diagnostyka obrazowa w ciąży. Stanowisko grupy ekspertów polskiego Klinicznego Forum Obrazowania Serca i Naczyń. Kardiologia Polska. 2013; 71(11): 1194–1203.
  23. Sliwa K, Mebazaa A, Hilfiker-Kleiner D, et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail. 2017; 19(9): 1131–1141.
  24. Hilfiker-Kleiner D, Haghikia A, Masuko D, et al. Outcome of subsequent pregnancies in patients with a history of peripartum cardiomyopathy. European Journal of Heart Failure. 2017; 19(12): 1723–1728.
  25. Ersbøll AS, Johansen M, Damm P, et al. Peripartum cardiomyopathy in Denmark: a retrospective, population-based study of incidence, management and outcome. Eur J Heart Fail. 2017; 19(12): 1712–1720.
  26. Perveen S, Ainuddin J, Jabbar S, et al. Peripartum cardiomyopathy: Frequency and predictors and indicators of clinical outcome. J Pak Med Assoc. 2016; 66(12): 1517–1521.
  27. Wu VCC, Chen TH, Yeh JK, et al. Clinical outcomes of peripartum cardiomyopathy: a 15-year nationwide population-based study in Asia. Medicine (Baltimore). 2017; 96(43): e8374.
  28. McNamara DM, Elkayam U, Alharethi R, et al. IPAC Investigators. Clinical Outcomes for Peripartum Cardiomyopathy in North America: Results of the IPAC Study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015; 66(8): 905–914.
  29. Kolte D, Khera S, Aronow WS, et al. Temporal trends in incidence and outcomes of peripartum cardiomyopathy in the United States: a nationwide population-based study. J Am Heart Assoc. 2014; 3(3): e001056.
  30. Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. -Results from the Japanese Nationwide survey of peripartum cardiomyopathy-. Circ J. 2011; 75(8): 1975–1981.
  31. Pillarisetti J, Kondur A, Alani A, et al. Peripartum cardiomyopathy: predictors of recovery and current state of implantable cardioverter-defibrillator use. J Am Coll Cardiol. 2014; 63(25 Pt A): 2831–2839.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl